ACE-031 (also called Ramatercept) is an investigational recombinant fusion protein studied for its ability to promote muscle growth by binding to myostatin and other proteins that naturally restrict muscle development. If you are a researcher or science-curious reader trying to make sense of the published data, this guide covers what the clinical record actually says, how dosage protocols were structured in human trials, and where ACE-031 sits relative to other myostatin-pathway compounds. PeptideValidation.com compiles peer-reviewed reference data on ACE-031 so researchers can verify the numbers without chasing down a dozen separate sources.

What Is ACE-031? A Plain-Language Definition

ACE-031 is a soluble ActRIIA-Fc fusion protein that acts as a decoy receptor for myostatin (GDF-8), GDF-11, and activin A, three proteins that suppress skeletal muscle growth. By sequestering these ligands before they can bind muscle cells, ACE-031 removes a natural brake on muscle hypertrophy. It was developed by Acceleron Pharma and advanced into Phase 2 clinical trials between 2010 and 2013.

ACE-031 pairs the extracellular domain of activin receptor type IIA (ActRIIA) with a human IgG1 Fc region. That combination creates a circulating protein that floats in the bloodstream, intercepts myostatin and related TGF-beta family members, and prevents them from reaching membrane-bound receptors on muscle cells.

The molecular weight of ACE-031 in its dimeric form is roughly 100 kDa. Recombinant production uses CHO (Chinese hamster ovary) cell lines, and reference-grade material is characterized by SDS-PAGE, SEC-HPLC, and ELISA-based binding assays. Those specifications matter to researchers who need to confirm they are working with material that matches what was used in published studies.

Acceleron Pharma (now part of Merck) is the originating developer. Their Phase 2 program in Duchenne muscular dystrophy (DMD) produced the most detailed human pharmacokinetic and pharmacodynamic data available on ACE-031 to date. Any serious review of this compound starts with that clinical record.

Because ACE-031 traps multiple ligands, not just myostatin, it differs from more targeted approaches like bimagrumab, which is a monoclonal antibody directed specifically at ActRIIA. That breadth of ligand coverage is both a research advantage and a documented safety consideration.

ACE-031 Dosage Protocols From Published Human Trials

In Phase 2 DMD trials, ACE-031 was administered subcutaneously at doses ranging from 0.1 mg/kg to 3.0 mg/kg, with injections every four weeks for up to three doses. Lean body mass gains were statistically significant at 12 weeks in the higher dose cohorts. These ACE-031 dosage benchmarks come from peer-reviewed clinical study reports, not anecdotal sources.

The Acceleron Phase 2 trial enrolled boys aged 4 to 16 with confirmed DMD. The dose-escalation design tested subcutaneous injections at 0.1, 0.3, 1.0, and 3.0 mg/kg, each given once every 28 days for three cycles. That quarterly-repeat cadence reflects the serum half-life of ACE-031, which sits at approximately 10 to 14 days in humans due to FcRn-mediated recycling conferred by the IgG1 Fc domain.

Lean body mass, measured by DEXA scan, increased significantly in the 1.0 and 3.0 mg/kg cohorts at the 12-week mark. The magnitude of gain varied by dose but was detectable above placebo at both levels. Bone mineral density also increased, an expected downstream effect of broader ActRIIA pathway inhibition.

For researchers designing preclinical studies, those human pharmacokinetic parameters, half-life of 10 to 14 days and subcutaneous bioavailability documented in the published protocol, provide the scaffolding for allometric scaling to animal models. PeptideValidation.com lists these parameters with direct citations to the primary literature so researchers can trace each number back to its source.

One practical note on ACE-031 peptide dosage discussions that circulate in research forums: the clinical trial used milligrams per kilogram of body weight, not fixed milligram amounts. Comparisons that drop the per-kilogram denominator produce numbers that are not directly comparable to the published record and should be treated with caution.

ACE-031 Cycle Structure: What the Clinical Program Tells Us

The Phase 2 ACE-031 cycle consisted of three subcutaneous injections spaced 28 days apart, followed by a 12-week observation window. That structure produced measurable lean mass gains and was the longest dosing period studied in a controlled human trial before the program was paused in 2013.

A 'cycle' in the context of ACE-031 research means the repeated-dosing schedule used to achieve sustained ActRIIA inhibition. Three monthly doses were enough to produce statistically significant lean mass changes in the DMD pediatric cohort. That tells researchers two things: the compound accumulates biological effect within a relatively short window, and repeat dosing is necessary to maintain pathway suppression given the half-life of 10 to 14 days.

The 12-week endpoint is practically important. Most ACE-031 results in bodybuilding or fitness-adjacent discussions reference this timeframe because it maps directly to the published trial data. Gains documented outside a controlled clinical trial cannot be verified against the same DEXA-based methodology, so cross-comparisons require careful qualification.

The program pause in 2013 means no longer-duration cycle data exists from controlled human trials. Researchers extrapolating to 24-week or longer hypothetical protocols are working beyond the evidence base. That gap is worth flagging explicitly in any study design that cites ACE-031's clinical history.

For preclinical ACE-031 cycle design, published mouse and non-human primate studies used varying dosing intervals, some as short as twice-weekly. Those protocols, also indexed at PeptideValidation.com, give researchers a broader picture of how dosing frequency affects pharmacodynamic outcomes across species.

ACE-031 vs Follistatin 344: Key Mechanism Differences

ACE-031 vs follistatin 344 comes down to mechanism breadth. ACE-031 is a recombinant fusion protein that blocks ActRIIA signaling upstream, trapping myostatin, GDF-11, and activin A simultaneously. Follistatin 344 is a naturally occurring binding protein that sequesters activins and myostatin but acts through a different structural route and has a distinct off-target profile.

Follistatin 344 refers to a specific isoform of follistatin, a glycoprotein that binds and neutralizes activins and myostatin by direct protein-protein interaction rather than receptor mimicry. ACE-031 mimics the receptor itself, presenting a soluble version of ActRIIA that intercepts ligands before they reach the cell surface.

The practical implication for researchers is specificity. Follistatin 344 has a particularly high affinity for activin A and activin B, with somewhat lower relative affinity for myostatin compared to ACE-031's designed trap. ACE-031's Fc fusion format also extends its serum half-life well beyond that of native follistatin, which is cleared much faster.

Bone density effects differ too. ACE-031's broad ActRIIA blockade produced measurable bone mineral density increases in the DMD trial, a finding not consistently replicated with follistatin-based approaches. That difference matters for research programs interested in musculoskeletal outcomes beyond pure muscle mass.

Safety profiles also diverge. The ACE-031 program was paused due to vascular adverse events, including nosebleeds and telangiectasia, attributed to off-target ActRIIA inhibition in vascular tissue. Follistatin 344 carries a different risk profile rooted in its activin-neutralizing activity. Researchers comparing the two compounds should treat the published adverse event data for each as separate bodies of evidence rather than interchangeable.

Both compounds sit firmly in the investigational category. Neither has regulatory approval for human use outside a clinical trial context.

ACE-031 Side Effects: What the Phase 2 Record Documents

Documented ACE-031 side effects from the Phase 2 DMD trial include epistaxis (nosebleeds), gingival bleeding, telangiectasia (small dilated blood vessels visible on the skin), and injection-site reactions. These vascular effects are attributed to ActRIIA pathway inhibition in non-muscle tissues and were the primary reason Acceleron Pharma paused the program in 2013.

The adverse events observed in the DMD trial were not trivial. Nosebleeds appeared in multiple participants and were severe enough in some cases to require medical management. Telangiectasia, small clusters of dilated capillaries visible on the skin, emerged as a signal that ActRIIA inhibition was affecting vascular tissue, not just skeletal muscle.

This makes biological sense. The ActRIIA pathway is active in endothelial cells, and broad ligand trapping by ACE-031 disrupts signaling that those cells rely on for vascular maintenance. Myostatin-specific antibodies like those in development post-2013 were partly motivated by a desire to avoid exactly this off-target exposure.

Gingival (gum) bleeding was also reported, consistent with vascular fragility rather than a coagulation-pathway problem. Published clinical study reports note that these events appeared to be dose-dependent, clustering more frequently in the higher milligram-per-kilogram cohorts.

For researchers referencing ACE-031 side effects in literature reviews or grant applications, the 2013 Acceleron clinical summary and the primary publication by Attie et al. are the most cited sources. PeptideValidation.com links directly to those documents so researchers do not have to hunt through ClinicalTrials.gov independently.

These findings are also relevant context for anyone reviewing ACE-031 1mg benefits discussions in fitness or muscle research spaces. The clinical record shows that even lower doses produced biological activity, which means the safety considerations documented at higher doses are mechanistically relevant across the dose range.

ACE-031 Results in Context: Lean Mass Gains From Controlled Data

Phase 2 trial data showed statistically significant lean body mass increases at 12 weeks in DMD patients receiving ACE-031 at 1.0 and 3.0 mg/kg. DEXA scan measurements confirmed gains in lean mass alongside increases in bone mineral density. These are the only controlled human ACE-031 results published to date.

The lean mass gains documented in the DMD trial are the most cited ACE-031 results in bodybuilding and muscle-research discussions. It is worth being precise about what the data says and what it does not say.

The trial population was pediatric boys with DMD, a condition in which muscle is already degrading due to dystrophin deficiency. Gains in that population reflect the compound's ability to slow or partially reverse atrophy in a disease state. Extrapolating those results to healthy, resistance-trained adults requires a separate evidentiary step that the clinical record does not provide.

The magnitude of lean mass gain was statistically significant but was not uniformly large across all dose groups. The 0.1 mg/kg cohort showed smaller and less consistent effects. The higher dose groups produced clearer signals, which is consistent with dose-dependent pharmacodynamics.

Bone mineral density increases were a secondary endpoint and also reached statistical significance. That finding has attracted interest from researchers studying osteoporosis and bone fragility conditions, extending ACE-031's relevance beyond pure muscle-wasting research.

No controlled data exists on ACE-031 results in healthy subjects or trained athletes. Any claims about performance outcomes in those populations are speculative relative to the peer-reviewed record. PeptideValidation.com's reference data index covers the primary literature endpoints so researchers can assess exactly what was and was not measured.

How PeptideValidation.com Organizes ACE-031 Reference Data

PeptideValidation.com aggregates ACE-031 reference data including sequence specifications, published pharmacokinetic parameters, trial outcome summaries, and purity benchmarks. Each data point links to its primary source so downstream citations remain traceable. The goal is one citable location instead of cross-referencing ClinicalTrials.gov, primary journals, and manufacturer spec sheets separately.

Researchers spend a surprising amount of time chasing citations across multiple databases. A molecular weight figure from a manufacturer's spec sheet may not match the value reported in a peer-reviewed pharmacokinetic study, and both may differ from what appears in a clinical trial registry. That inconsistency slows literature review and creates ambiguity in grant applications.

PeptideValidation.com resolves that problem for ACE-031 by presenting reference specifications side by side with their sourcing. The molecular weight of approximately 100 kDa (dimeric form), the isoelectric point, the 10 to 14 day serum half-life, and the purity thresholds used in published studies all appear in one indexed location with links to primary literature.

The site also includes comparative reference data for related ActRIIA inhibitors like bimagrumab, which helps researchers distinguish mechanism differences without switching platforms. That side-by-side structure is particularly useful when writing a background section that contextualizes ACE-031 within the broader myostatin inhibitor field.

For a deeper look at the full clinical history, mechanism of action, and regulatory context of ACE-031, the hub article on PeptideValidation.com covers all of that in one place. It is the logical next read after this overview, especially if you are designing a study or preparing a literature review.

All data on PeptideValidation.com links back to its primary source. If a number appears without a citation, it is flagged as unverified. That standard keeps the reference layer clean and defensible when researchers need to cite downstream.

Frequently asked questions